Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q4 2017 · 10-K
Revenue$1.37M$1.37M+22.3% vs Q4 2016 Net Income-$1.85M-$1.85MN/M vs Q4 2016 EPS Diluted-$0.03-$0.03N/M vs Q4 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$1,213,000N/M Free Cash Flowderived-$1,469,000N/M Margins · derivedGross margin36.4%+40.6 pt vs Q4 2016
Operating margin-136.1%−24.1 pt vs Q4 2016
Net margin-135.3%−29.5 pt vs Q4 2016
ended Jun 30, 2017 · filed Sep 28, 2017 · 90 d after period end